CR20150509A - Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina - Google Patents
Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrinaInfo
- Publication number
- CR20150509A CR20150509A CR20150509A CR20150509A CR20150509A CR 20150509 A CR20150509 A CR 20150509A CR 20150509 A CR20150509 A CR 20150509A CR 20150509 A CR20150509 A CR 20150509A CR 20150509 A CR20150509 A CR 20150509A
- Authority
- CR
- Costa Rica
- Prior art keywords
- naftiridine
- integrine
- alfa
- antagonists
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de fórmula (I) o una sal del mismo en la que R1 representa un átomo de hidrógeno, un grupo metilo o un grupo etilo R2 es un átomo de hidrógeno o un átomo de flúorR3 representa un átomo de hidrógeno, un grupo metilo o un grupoetilo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1305668.4A GB201305668D0 (en) | 2013-03-28 | 2013-03-28 | Avs6 Integrin Antagonists |
| PCT/EP2014/056013 WO2014154725A1 (en) | 2013-03-28 | 2014-03-26 | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20150509A true CR20150509A (es) | 2016-03-04 |
Family
ID=48444909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20150509A CR20150509A (es) | 2013-03-28 | 2015-09-28 | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US10023568B2 (es) |
| EP (2) | EP2989100B1 (es) |
| JP (1) | JP6095847B2 (es) |
| KR (2) | KR102042141B1 (es) |
| CN (1) | CN105189499B (es) |
| AR (1) | AR095768A1 (es) |
| AU (1) | AU2014243068C1 (es) |
| BR (1) | BR112015024530A8 (es) |
| CA (1) | CA2903358A1 (es) |
| CL (1) | CL2015002860A1 (es) |
| CR (1) | CR20150509A (es) |
| CY (1) | CY1120188T1 (es) |
| DK (1) | DK2989100T3 (es) |
| DO (1) | DOP2015000251A (es) |
| EA (1) | EA027305B1 (es) |
| ES (1) | ES2665597T3 (es) |
| GB (1) | GB201305668D0 (es) |
| HR (1) | HRP20180528T1 (es) |
| HU (1) | HUE036750T2 (es) |
| IL (1) | IL241184A0 (es) |
| LT (1) | LT2989100T (es) |
| MA (1) | MA38540B1 (es) |
| ME (1) | ME02987B (es) |
| MX (1) | MX363288B (es) |
| NO (1) | NO2989100T3 (es) |
| NZ (1) | NZ629025A (es) |
| PE (1) | PE20151606A1 (es) |
| PH (1) | PH12015502232B1 (es) |
| PL (1) | PL2989100T3 (es) |
| PT (1) | PT2989100T (es) |
| RS (1) | RS57220B1 (es) |
| SG (1) | SG11201506813QA (es) |
| SI (1) | SI2989100T1 (es) |
| SM (1) | SMT201800247T1 (es) |
| TW (1) | TWI632143B (es) |
| UA (1) | UA114952C2 (es) |
| UY (1) | UY35505A (es) |
| WO (1) | WO2014154725A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3929196B1 (en) | 2013-09-24 | 2023-08-23 | FUJIFILM Corporation | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof |
| GB201417094D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| WO2016142426A1 (en) | 2015-03-11 | 2016-09-15 | Glaxosmithkline Intellectual Property Development Limited | Tslp binding proteins |
| GB201615588D0 (en) | 2016-09-14 | 2016-10-26 | Glaxosmithkline Ip Dev Ltd | TSLP Binding Proteins |
| GB201604589D0 (en) * | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604681D0 (en) * | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| KR102506324B1 (ko) | 2016-11-08 | 2023-03-03 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 v 인테그린 억제제로서의 시클로부탄- 및 아제티딘-함유 모노 및 스피로시클릭 화합물 |
| JP7128811B2 (ja) | 2016-11-08 | 2022-08-31 | ブリストル－マイヤーズ スクイブ カンパニー | アルファｖインテグリン阻害剤としてのアゾールアミドおよびアミン |
| CA3042693A1 (en) * | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | Pyrrole amides as .alpha.v integrin inhibitors |
| HRP20220990T1 (hr) | 2016-11-08 | 2022-11-11 | Bristol-Myers Squibb Company | 3-supstituirane propionske kiseline kao inhibitori alfa v integrina |
| WO2018089357A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| EP3589627A4 (en) | 2017-02-28 | 2020-08-05 | Morphic Therapeutic, Inc. | (ALPHA-V) (BETA-6) INHIBITORS INTEGRIN |
| EP3760202A1 (en) | 2017-02-28 | 2021-01-06 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2019094319A1 (en) | 2017-11-07 | 2019-05-16 | Bristol-Myers Squibb Company | Pyrrolopyrazine derivatives as alpha v integrin inhibitors |
| CA3093225A1 (en) | 2018-03-07 | 2019-09-12 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TWI841573B (zh) * | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| WO2020047208A1 (en) * | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| PL3844162T3 (pl) | 2018-08-29 | 2025-06-09 | Morphic Therapeutic, Inc. | Inhibitory integryny alfa v beta 6 |
| EP3617206A1 (en) | 2018-08-29 | 2020-03-04 | Morphic Therapeutic, Inc. | Integrin inhibitors |
| EP3843728B1 (en) * | 2018-08-29 | 2025-04-30 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| WO2022183360A1 (en) * | 2021-03-02 | 2022-09-09 | Tsao Yeou Ping | Short synthetic peptide and their uses for treating dry eye disease |
| JP2025541280A (ja) | 2022-12-14 | 2025-12-18 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 肝外送達のためのアルファ－ｖベータ－６（αｖβ６）インテグリンリガンド |
| US20240245682A1 (en) * | 2022-12-27 | 2024-07-25 | Pliant Therapeutics, Inc. | Alpha-v-beta-8 integrin inhibitors and uses thereof |
| WO2025259747A2 (en) | 2024-06-12 | 2025-12-18 | Alnylam Pharmaceuticals, Inc. | Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof |
| WO2025259743A1 (en) | 2024-06-12 | 2025-12-18 | Alnylam Pharmaceuticals, Inc. | Dual conjugate compounds for extrahepatic delivery |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| JP2002508323A (ja) * | 1997-12-17 | 2002-03-19 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
| GEP20032921B (en) | 1997-12-17 | 2003-03-25 | Merck & Co Inc | Integrin Receptor Antagonists Pharmaceutical Compositions Containing the Same and Methods for Treatment |
| IL146378A0 (en) | 1999-06-02 | 2002-07-25 | Merck & Co Inc | Alpha v integrin receptor antagonists |
| WO2000078317A1 (en) | 1999-06-23 | 2000-12-28 | Merck & Co., Inc. | Integrin receptor antagonists |
| JP2003510360A (ja) | 1999-10-04 | 2003-03-18 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
| HUP0203246A3 (en) * | 1999-11-08 | 2003-12-29 | Merck & Co Inc | Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists |
| US6933304B2 (en) | 2000-06-15 | 2005-08-23 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| ATE353219T1 (de) | 2000-07-26 | 2007-02-15 | Merck & Co Inc | Alpha v integrin-rezeptor-antagonisten |
| AU2001290772A1 (en) | 2000-09-14 | 2002-03-26 | Merck And Co., Inc. | Alpha v integrin receptor antagonists |
| EP1349548A4 (en) | 2001-01-03 | 2004-06-02 | Merck & Co Inc | METHOD AND COMPOSITIONS FOR TREATING PERIODONTOSIS |
| DE10112771A1 (de) * | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
| CA2478833C (en) | 2002-03-13 | 2015-11-10 | Biogen, Inc. | Anti-.alpha.v.beta.6 antibodies |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| WO2004058254A1 (en) | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| US6932865B2 (en) | 2003-04-11 | 2005-08-23 | Lockheed Martin Corporation | System and method of making single-crystal structures through free-form fabrication techniques |
| CN1901958B (zh) | 2003-11-03 | 2011-03-09 | 葛兰素集团有限公司 | 流体分配装置 |
| US7705018B2 (en) | 2007-03-23 | 2010-04-27 | Amgen Inc. | Substituted quinolines and their uses in treatment of inflammatory and related conditions |
| US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| EP2211615A4 (en) | 2007-10-22 | 2010-10-13 | Glaxosmithkline Llc | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS |
| WO2011111880A1 (ko) | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| AU2014324426A1 (en) | 2013-09-30 | 2016-04-21 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2016134223A2 (en) | 2015-02-19 | 2016-08-25 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| JP2018515424A (ja) | 2015-03-10 | 2018-06-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗アルファｖベータ１インテグリン阻害剤及び使用方法 |
| GB201604589D0 (en) | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
-
2013
- 2013-03-28 GB GBGB1305668.4A patent/GB201305668D0/en not_active Ceased
-
2014
- 2014-03-26 MA MA38540A patent/MA38540B1/fr unknown
- 2014-03-26 UY UY0001035505A patent/UY35505A/es not_active Application Discontinuation
- 2014-03-26 NO NO14712666A patent/NO2989100T3/no unknown
- 2014-03-26 CN CN201480018839.6A patent/CN105189499B/zh not_active Expired - Fee Related
- 2014-03-26 AU AU2014243068A patent/AU2014243068C1/en not_active Ceased
- 2014-03-26 ME MEP-2018-83A patent/ME02987B/me unknown
- 2014-03-26 SG SG11201506813QA patent/SG11201506813QA/en unknown
- 2014-03-26 AR ARP140101378A patent/AR095768A1/es unknown
- 2014-03-26 PL PL14712666T patent/PL2989100T3/pl unknown
- 2014-03-26 RS RS20180537A patent/RS57220B1/sr unknown
- 2014-03-26 UA UAA201508518A patent/UA114952C2/uk unknown
- 2014-03-26 SM SM20180247T patent/SMT201800247T1/it unknown
- 2014-03-26 TW TW103111317A patent/TWI632143B/zh not_active IP Right Cessation
- 2014-03-26 HR HRP20180528TT patent/HRP20180528T1/hr unknown
- 2014-03-26 JP JP2016504647A patent/JP6095847B2/ja not_active Expired - Fee Related
- 2014-03-26 BR BR112015024530A patent/BR112015024530A8/pt not_active IP Right Cessation
- 2014-03-26 WO PCT/EP2014/056013 patent/WO2014154725A1/en not_active Ceased
- 2014-03-26 LT LTEP14712666.8T patent/LT2989100T/lt unknown
- 2014-03-26 SI SI201430687T patent/SI2989100T1/en unknown
- 2014-03-26 EP EP14712666.8A patent/EP2989100B1/en active Active
- 2014-03-26 US US14/778,095 patent/US10023568B2/en not_active Expired - Fee Related
- 2014-03-26 KR KR1020177024389A patent/KR102042141B1/ko not_active Expired - Fee Related
- 2014-03-26 EA EA201591503A patent/EA027305B1/ru not_active IP Right Cessation
- 2014-03-26 ES ES14712666.8T patent/ES2665597T3/es active Active
- 2014-03-26 KR KR1020157031064A patent/KR101775085B1/ko not_active Expired - Fee Related
- 2014-03-26 NZ NZ629025A patent/NZ629025A/en not_active IP Right Cessation
- 2014-03-26 MX MX2015013742A patent/MX363288B/es unknown
- 2014-03-26 CA CA2903358A patent/CA2903358A1/en not_active Abandoned
- 2014-03-26 PE PE2015002064A patent/PE20151606A1/es active IP Right Grant
- 2014-03-26 PT PT147126668T patent/PT2989100T/pt unknown
- 2014-03-26 DK DK14712666.8T patent/DK2989100T3/en active
- 2014-03-26 EP EP18157255.3A patent/EP3360876A1/en not_active Withdrawn
- 2014-03-26 HU HUE14712666A patent/HUE036750T2/hu unknown
-
2015
- 2015-09-06 IL IL241184A patent/IL241184A0/en active IP Right Grant
- 2015-09-24 PH PH12015502232A patent/PH12015502232B1/en unknown
- 2015-09-25 CL CL2015002860A patent/CL2015002860A1/es unknown
- 2015-09-28 CR CR20150509A patent/CR20150509A/es unknown
- 2015-09-28 DO DO2015000251A patent/DOP2015000251A/es unknown
-
2018
- 2018-05-09 CY CY20181100479T patent/CY1120188T1/el unknown
- 2018-06-13 US US16/007,584 patent/US10450312B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20150509A (es) | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina | |
| CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
| MX378288B (es) | Inhibidores de pirimidina del fgfr4. | |
| UA113643C2 (xx) | N-цикліламіди як нематоциди | |
| CU24309B1 (es) | Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen | |
| CR20140525A (es) | Compuestos de N-alquiltriazol como antagonistas de LPAR | |
| CR20150447A (es) | Nuevos derivados de pirazol | |
| EA201692219A1 (ru) | Способы получения противовирусных соединений | |
| MX373247B (es) | Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina. | |
| CR20150250A (es) | Nuevos derivados de piridina | |
| CR20150440A (es) | Nuevos derivados de piridina | |
| MX370901B (es) | 3-(4-isobutil-2-metilfenil)-propanal como ingrediente de perfume. | |
| UA116395C2 (uk) | ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ | |
| EA201591349A1 (ru) | Способ получения вортиоксетина | |
| CR20150511A (es) | Nuevos derivados de purina | |
| CR20150555A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina | |
| PH12015502462A1 (en) | Imidazo-triazine derivatives as pde10 inhibitors | |
| EA201591915A1 (ru) | Соединения феноксиэтил дигидро-1h-изохинолина | |
| BR112016028022A2 (pt) | compostos de sulfonamida e seus usos como inibidores de stat5 | |
| MX373636B (es) | Compuestos de azetidiniloxifenilpirrolidina. | |
| CY1121116T1 (el) | Νεα μεθοδος για την συνθεση αγομελατινης | |
| DOP2016000062A (es) | Derivados de indol-urea de glucopiranosil sustituido y su uso como inhibidores de sglt | |
| NI201200039A (es) | Nuevos derivados dihidro - oxazolobenzodiazepinonas, su procedi | |
| DOP2017000016A (es) | Nueva sal de disoproxilo de tenofovir | |
| EA201600032A1 (ru) | Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина |